Swiss drugmakers Roche and Novartis each won European approval for drugs on March 30 in a sign that the rival Basel-based companies are increasingly competing for the same patients.
Novartis is closing a manufacturing facility in Longmont, Colorado acquired by company subsidiary AveXis during 2019 that has provided additional production capacity for Zolgensma, a gene therapy treatment for spinal muscular atrophy.
Novartis’ drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.
CureVac NV inked a deal with Switzerland’s Novartis AG to manufacture the German biopharmaceutical company’s Covid-19 vaccine candidate, CVnCoV.
Novartis and the Bill & Melinda Gates Foundation have partnered on a single-dose, in vivo gene therapy for sickle cell disease (SCD).
Novartis’ Entresto is the first therapy approved in the United States to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).
Sandoz, a division of Swiss-based Novartis, inked a deal to buy U.K.-based GlaxoSmithKline’s cephalosporin antibiotics business.
The U.S. Food and Drug Administration granted Novartis’ ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment.
BeiGene Ltd. will partner with Swiss firm Novartis AG to develop, manufacture and commercialize the China-based biotechnology company’s cancer drug tislelizumab.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.